Provided by Tiger Fintech (Singapore) Pte. Ltd.

EVEREST MED-B

47.400
+1.0002.16%
Volume:7.31M
Turnover:352.66M
Market Cap:15.50B
PE:-13.73
High:49.500
Open:48.550
Low:46.900
Close:46.400
Loading ...

Everest Medicines to Drop B Marker from Stock Short Name

MT Newswires Live
·
25 Apr

HK Movers | Biotech Stocks Gain Again With Everest Medicines up 5%

Tiger Newspress
·
25 Apr

The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%

Simply Wall St.
·
08 Apr

Stock Track | Everest Medicines Plummets 5.09% Despite Strong Revenue Growth, as Net Loss Concerns Investors

Stock Track
·
26 Mar

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

THOMSON REUTERS
·
26 Mar

Press Release: Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

Dow Jones
·
26 Mar

BRIEF-Everest Medicines Posts FY Net Income RMB -1,041.4 Million

Reuters
·
26 Mar

Everest Medicines FY Revenue RMB 706.7 Million

THOMSON REUTERS
·
26 Mar

Everest Medicines Announces FDA Clearance of Ind Application for Tumor-Associated Antigen Vaccine Evm14

THOMSON REUTERS
·
24 Mar

High Growth Tech Stocks in Asia to Watch for Promising Growth

Simply Wall St.
·
10 Mar

Everest Medicines Shares Surge 18% as First Patient Dosed in Cancer Drug Trial

MT Newswires Live
·
07 Mar

Everest Medicines Announces First Patient Dosed With Evm16, Its First Internally Developed Personalized Mrna Cancer Vaccine

THOMSON REUTERS
·
06 Mar

Everest Medicines Ltd - Evm16 Shows Synergistic Effect With Pd-1 Antibody in Preclinical Data

THOMSON REUTERS
·
06 Mar

Everest Medicines Ltd - Evm16 Well Tolerated and Safe in Preclinical Toxicity Studies

THOMSON REUTERS
·
06 Mar

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.
·
03 Mar

Stock Track | Everest Medicines Plummets 5.04% on Controlling Shareholder's Block Trade

Stock Track
·
09 Jan

Everest Medicines Clarifies Unusual Price, Trading Volume Movements

MT Newswires Live
·
09 Jan

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1B/2a Clinical Trial of Ever001, a Novel Btk Inhibitor for the Treatment of Primary Membranous Nephropathy

THOMSON REUTERS
·
04 Dec 2024

Everest Medicines to Hold Investor Calls on Data Results From Ever001 Phase 1B/2a Clinical Study in Primary Membranous Nephropathy

THOMSON REUTERS
·
27 Nov 2024

BRIEF-Everest Medicines Says PwC Agreed To Resign As Auditors Of Co

Reuters
·
15 Nov 2024